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Abstract
High levels of pro-angiogenic factors, leptin, IL-1, Notch and VEGF (ligands and receptors), are found in breast cancer, which
is commonly correlated with metastasis and lower survival of patients. We have previously reported that leptin induces the
growth of breast cancer and the expression of VEGF/VEGFR-2 and IL-1 system. We hypothesized that Notch, IL-1 and leptin
crosstalk outcome (NILCO) plays an essential role in the regulation of leptin-mediated induction of proliferation/migration
and expression of pro-angiogenic molecules in breast cancer. To test this hypothesis, leptin’s effects on the expression and
activation of Notch signaling pathway and VEGF/VEGFR-2/IL-1 were determined in mouse (4T1, EMT6 and MMT) breast
cancer cells. Remarkably, leptin up-regulated Notch1-4/JAG1/Dll-4, Notch target genes: Hey2 and survivin, together with IL-
1 and VEGF/VEGFR-2. RNA knockdown and pharmacological inhibitors of leptin signaling significantly abrogated activity of
reporter gene-luciferase CSL (RBP-Jk) promoter, showing that it was linked to leptin-activated JAK2/STAT3, MAPK, PI-3K/
mTOR, p38 and JNK signaling pathways. Interestingly, leptin upregulatory effects on cell proliferation/migration and pro-
angiogenic factors Notch, IL-1 and VEGF/VEGFR-2 were abrogated by a c-secretase inhibitor, DAPT, as well as siRNA against
CSL. In addition, blockade of IL-1R tI inhibited leptin-induced Notch, Hey2 and survivin as well as VEGF/VEGFR-2 expression.
These data suggest leptin is an inducer of Notch (expression/activation) and IL-1 signaling modulates leptin effects on
Notch and VEGF/VEGFR-2. We show for the first time that a novel unveiled crosstalk between Notch, IL-1 and leptin (NILCO)
occurs in breast cancer. Leptin induction of proliferation/migration and upregulation of VEGF/VEGFR-2 in breast cancer cells
were related to an intact Notch signaling axis. NILCO could represent the integration of developmental, pro-inflammatory
and pro-angiogenic signals critical for leptin-induced cell proliferation/migration and regulation of VEGF/VEGFR-2 in breast
cancer. Targeting NILCO might help to design new pharmacological strategies aimed at controlling breast cancer growth
and angiogenesis.
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Introduction
Notch, IL-1 and leptin are notorious pro-angiogenic factors whose
over-expression characterized growth of breast cancer, metastasis and
poor prognosis. Notch signaling is essential for angiogenesis, functions
in an enormous diversity of developmental processes, and its
dysfunction is implicated in many cancer types. Notably, Notch and
leptin are pro-proliferation factors for many cell types [1,2,3,4].
Expression of Notch1 and its ligand, JAG1, is associated with the
poorest breast cancer survival and increased levels of VEGFR-2 [5,6].
Notch signaling is activated by ligand binding expressed by adjacent
cells, followed by ADAM/TACE and c-secretase cleavages that
produce the Notch intracellular domain (NICD). NICD interacts with
nuclear RBP-Jk or CBF1/Su(H)/Lag-1 (CSL) family of transcription
factors to activate Notch target genes (i.e. survivin, Hey2) [3]. The
GSIs or small molecule inhibitors of c- s e c r e t a s ea b r o g a t eN o t c h
actions in cancer, but they show many side-effects [3].
Increased levels of IL-1 system components (ligands: IL-1a/-b;
antagonist: IL-1Ra and receptor: IL-1R tI), are found in breast
cancer [7]. IL-1 binding to IL-1R tI activates p38 MAPK and NF-
kB signaling pathways to induce VEGF [8] and VEGFR-2
expression (Gonzalez-Perez; Manuscript in preparation). IL-1
signaling promotes breast cancer development. Indeed, blockade
of IL-1R tI with IL-1Ra has shown to negatively impact on
angiogenesis and growth of human breast cancer xenografts in
mouse models [7,9].
Obesity, a pandemic in the US, is associated with more than
100,000 incidents of cancer in the US every year particularly
cancers of the breast, colon, and endometrium. Obese breast
cancer patients have increased mortality compared to non-obese
patients [10]. Leptin is mainly produced by adipose tissue, but also
abnormally expressed together with its receptor (OB-R) in BC cells
[11,12]. Higher levels of leptin are found in female, postmeno-
pausal women and obese individuals. Accumulating evidence show
leptin is an important pro-angiogenic, pro-inflammatory and
mitogenic factor [13,14], whose actions are reinforced through
crosstalk with cytokines/growth factors [3,5,15,16,17,18]. Leptin
signals through activation of its receptor, OB-R that induces
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AKT1) and non-canonical signaling pathways (PKC, JNK and
p38 MAP kinase) to exert its biological effects in food intake,
energy balance, and adiposity as well as in the immune and
endocrine systems [19,20].
We have previously shown that leptin signaling could give an
additional advantage to breast cancer by up-regulating VEGF/
VEGFR-2 before hypoxia is manifested [18]. Remarkably,
VEGF/VEGFR-2 directly regulates tumor angiogenesis and also
works as an essential autocrine/paracrine process for breast cancer
cell proliferation and survival [5]. Moreover, it was recently
reported that leptin is able to phosphorylate VEGFR-2 in absence
of VEGF in human endothelial cells [21]. Increasing evidence
suggest leptin signaling could be an important link between breast
cancer incidence/growth and obesity. Restriction of caloric intake
(25%) reduces 7,12-dimethylbenz[a]anthracene (DMBA)-mam-
mary tumor incidence in rats [22]. Similar effects were found using
a pegylated leptin peptide receptor antagonist (PEG-LPrA2) for
inhibition of leptin signaling in lean and diet-obesity-induced mice
treated with DMBA [Gonzalez-Perez, Manuscript in preparation].
Furthermore, the elegant work of Dr. Cleary’s group has shown
that obese mice with deficiency in leptin signaling (ob/ob or db/db)
show a significantly lower incidence of mammary tumors than
their lean littermates. On the other hand, MMTV-TGF-a mice
have a proclivity to develop mammary tumors, but when crossed
with leptin/OB-R deficient mice, there is a reduced incidence of
tumors in their progeny [23,24]. Furthermore, we previously
demonstrated that the disruption of leptin signaling with PEG-
LPrA2 markedly reduced the growth of tumors in mouse models
of syngeneic and human breast cancer xenografts [25,26]. PEG-
LPrA29s effects were accompanied by a significant decrease in
VEGF/VEGFR-2, IL-1R tI, cyclin D1 and PCNA levels [25,26].
In line with these data, we recently provided a comprehensive
mechanism for leptin-mediated regulation of VEGF in breast
cancer cells [27]. In addition, we have shown that leptin
increases protein and mRNA levels of all components of the IL-1
system in breast cancer [18]. Leptin upregulation of VEGF
promoter was linked to AP1, HIF-1 and NF-kB [27] meanwhile
leptin-mediated activation IL-1a promoter was linked to SP1 and
NF-kB transcription factors [18]. Interestingly, leptin upregulation
of VEGF/VEGFR-2 in breast cancer was partially mediated by IL-
1/IL-1R tI signaling [18]. However, the molecular mechanisms of
leptin pro-angiogenic actions in breast cancer are still not fully
understood. Since Notch signaling and its crosstalks with many
signaling pathways play an important role in breast cancer cell
growth, migration, invasion, metastasis as well as angiogenesis [3],
we hypothesized that a crosstalk between Notch, IL-1 and leptin
signaling could impact on the expression of pro-angiogenic
molecules, and induction of cell proliferation and migration in
breast cancer. To test this hypothesis, we used mouse mammary
cancer cell lines (4T1, EMT6 and MMT) that differentially respond
to leptin and express OB-R, VEGF/VEGFR-2 and IL-1/IL-1R tI
[27]. Our results show for the first time that leptin is a regulator of
Notch expression and activation in breast cancer. Leptin-induction
of cell proliferation/migration along with VEGF/VEGFR-2 was
highly dependent of a novel unveiled crosstalk between Notch, IL-1
and leptin (NILCO) in breast cancer cells.
Results
Leptin induces the expression of Notch receptors and
ligands in breast cancer cells
Leptin upregulation of Notch component expression was
initially determined by immunohistochemistry. Figure 1A shows
representative pictures for leptin-mediated increase in protein
levels of Notch receptors (Notch1,2,3,4), ligand (DLL-4) and
targets (survivin, Hey2) in 4T1 cells. Western blot analyses further
assessed these findings in 4T1 cells. Leptin generally induced
protein expression of Notch receptors (Notch1,4) and ligands,
(JAG1, DLL-4) in a dose-response manner in the mouse
mammary cancer cells investigated (Figure 1 B–G). However,
the levels of JAG1 expression were downregulated by leptin in
4T1 cells, but DLL-4 was upregulated by leptin in all cells. Leptin
differentially up-regulated Notch receptors in mammary cancer
cells. In 4T1 cells leptin-mediated induction of Notch shows the
following pattern: Notch1, Notch2. Notch4.Notch3 and DLL-
4 (Figure 1B–C). In contrast, leptin induction of Notch in EMT6
cells was: Notch2.Notch1. Notch3.Notch4 and DLL-
4.JAG1 (Figure 1D–E). On the other hand, the pattern of
leptin-induction of Notch in MMT cells was: Notch4.Notch1,
Notch2.Notch3 and DLL-4.JAG1 (Figure 1F–G). The biolog-
ical relevance of the leptin-relative induction levels of Notch
receptors in each cell line remains to be investigated. We also
observed similar leptin effects on Notch signaling when we used
two human breast cancer cell lines, MCF-7 and MDA-MB-231
(data not shown).
Leptin-induced Notch signaling up-regulates Notch
mRNA and target genes: survivin and Hey2
To further investigate the effects of leptin on the transcriptional
expression of Notch, the next series of experiments were made
with 4T1 cells. In these cells leptin up-regulated the transcriptional
expression of Notch (Notch1-3, DLL-4) and target genes (Hey2,
survivin) (Figure 2A). Interestingly, leptin-induced effects on
transcriptional/translational regulation of the above molecules
were abrogated by DAPT (an inhibitor of Notch activation) (see
Figure 2A–B).
Leptin induced expression of Notch and its targets is
abrogated by CSL siRNA
In order to investigate whether leptin-induced regulation of
Notch/targets is also dependant of CSL regulation CLS-siRNA
was used. The addition of CSL-siRNA also significantly inhibits
leptin-induced expression of Notch receptors and targets, Hey2
and survivin (Figure 3). Interestingly, leptin also up-regulated CSL
protein expression (Figure 3A,B).
Several leptin-induced signals are involved in CSL
transcription
To investigate if leptin upregulates CSL (CBF) transcription,
4T1 cells were co-transfected with CSL-reporter-luciferase and
Renilla control-plasmid (pGL3-CBF). As expected, leptin signifi-
cantly induced firefly luciferase expression in CBF-Luc cells
(Figure 4). Next, to investigate which leptin-induced signals
regulate CSL, cells were treated with leptin and leptin plus siRNA
and pharmacological inhibitors of main leptin-induced kinases.
Treatment of cells with leptin and siRNA for STAT3, MEK1,
AKT1, mTOR, JNK and p38 MAPK significantly reduced basal
levels and leptin-mediated increase of CSL-Luc levels (Figure 4A).
WB analysis was used to assess whether siRNA treatment
effectively reduced the expression of kinases after 24 h
(Figure 4B). To further assess the role of leptin-induced kinases
on CSL expression several pharmacological inhibitors were used.
Inhibitors of canonic JAK2/STAT; MAPK/ERK 1/2 and PI-
3K/AKT and non-canonic signaling pathways JNK and p38
MAP kinases completely abrogated leptin-induced up-regulation
of CBF-Luc (Figure 4C).
NILCO Induces Growth/Migration and VEGF/VEGFR-2
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21467Figure 1. Leptin induces the expression of Notch and its molecular targets in mammary cancer cells. Representative results of leptin-
dose effects on increase in protein levels of Notch (ligands and receptors) and molecular targets as determined by immunocytochemistry in 4T1 cells
(A) and western blot (WB) in 4T1 (B and C), EMT6 (D and E) and MMT (F and G) cells. Cells were cultured for 24 h and leptin dose-induced (0, 0.6, 1.2
and 6.2 nM) effects were determined as described (See M &M). The WB results were normalized to b-actin as loading control and densitometric
analysis of bands was carried-out with the imageJ software. (a) P,0.05 when comparing levels of protein to control (basal). Data (mean 6 standard
error) representative results derived from a minimum of 3 independent experiments. Bar=200 mm.
doi:10.1371/journal.pone.0021467.g001
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cancer cell proliferation and migration
To explore the biological significance of leptin-Notch crosstalk in
breast cancer, we addressed the question whether the reported
induction of cell proliferation and migration by leptin is affected by
inhibition of Notch activation (DAPT; a c-secretase inhibitor) and/
or down regulation of its DNA-binding partner (CSL gene
knockdown using CSL-siRNA). Figure 5 shows leptin significantly
induced migration (Fig 5A-D) and proliferation of 4T1 cells in vitro
(Fig 5E–F). Remarkably, these leptin effects were completely
abrogated by inhibition of Notch signaling either with DAPT or
CSL-siRNA. Furthermore, the leptin-induction of Notch proteins/
activation paralleled the leptin-mediated induction of proliferation/
migration of breast cancer cells. In contrast, DAPT alone and
control-siRNA has no significant effects on basal or leptin-induced
4T1 cell migration or proliferation (see Figure 5A–F).
Leptin-induced Notch regulates the levels of pro-
angiogenic and pro-inflammatory factors
Leptin regulates the transcriptional (Figure 6A–F) and transla-
tional (Figure 6G–J and Figure 6M–P) expression of VEGF/
VEGFR-2 and IL-1a in 4T1 cells as determined by RT-PCR and
Figure 2. Leptin-mediated upregulation of protein and mRNA levels of Notch receptors and targets in mammary cancer cells are
abrogated by a c-secretase inhibitor (DAPT). Leptin-induced transcriptional expression of Notch receptors and targeted genes was abrogated by
DAPT in 4T1 cells. Levels of Notch receptors mRNA (A, Notch1; B, Notch2 and C, Notch3) and targeted genes (D, Hey2 and E, survivin) as determined by
real-time RT-PCR. GAPDH was used as internal control. (F–M) Representative results of leptin upregulation of protein levels of Notch1–3 and activated
NICD1 as well as Notch targeted genes, Hey2 and survivin in 4T1 cells as determined by western blot (WB). The WB results were normalized to b-actin as
loading control anddensitometric analysis of bands was carried-out with the imageJ software for (G) NICD1; (H) Notch1; (I) Notch 2; (J) Notch 3; (K) Hey2
and (M) survivin. 4T1 cells were cultured in a medium containing 0 or 1.2 nM leptin for 24 h. (a) P,0.05 when comparing levels of mRNA or protein to
control (basal). Data (mean 6 standard error) representative results derived from a minimum of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g002
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protein levels of ERa and OB-R. (Figure 6M, Q and R).
Moreover, we further determined that inhibition of Notch
activation (by DAPT) and CSL gene knockdown (by CSL-siRNA)
abrogated the leptin-induced effects on the above described
molecules at mRNA (Figure 6A–F) and protein levels (Figure 6G–
R). The effects of leptin, DAPT and CSL-siRNA on IL-1a and
VEGF levels in cell culture supernatants were further assessed by
ELISA. IL-1a and VEGF levels showed similar patterns (data not
shown) than those found by WB analysis.
Inhibition of IL-1R tI signaling negatively impacted on
leptin upregulation of Notch and target genes in breast
cancer cells
We further asked whether the blockade of IL-1R tI function also
impacts Notch signaling pathway. Figure 7 shows that in contrast
to control IgG, the blockade of IL-1/IL-1R tI signaling by IL-1R
tI antibody significantly reduced leptin-induced transcriptional
(Figure 7A–E) and translational (Figure 7F and Figure 7I–M)
upregulation of Notch1, 2, 3, and Notch target genes, Hey2 and
survivin in 4T1 cells. In addition, Notch1 NICD activation was
also dependant of IL-1 signaling (Figure 7H).
Discussion
Leptin is a growth and pro-angiogenic factor whose signals are
strongly linked to the growth of solid tumors, particularly, breast
cancer. We have previously shown that leptin induces growth and
angiogenesis in mouse syngeneic mammary tumors [25], human
breast cancer xenografts [26] and, in a mouse model for
endometriosis-like lesions [28]. Leptin pro-angiogenic effects seem
to be common in cancer since leptin differentially induces VEGF/
VEGFR-2 in endometrial cancer, but not in normal cells [29].
Moreover, leptin induces VEGF/VEGFR-2 expression, angio-
genesis and growth of human ovary cancer xenografts in nude
mice and in 7,12- dimethylbenz[a]anthracene (DMBA)-diet-
induced-obesity (DIO) mouse models of breast cancer (Gonza-
lez-Perez, Manuscript in preparation). Leptin-induced effects on
VEGF/VEGFR-2 expression and growth of tumors/endometri-
otic tissues were abrogated by leptin signaling inhibition using
antagonists of leptin receptor (PEG-LPrA) [25,26,28,29]. Although
all the mechanism(s) by which leptin contributes to tumor
development are unknown, it appears leptin stimulates an increase
in cell numbers, and the expression of VEGF/VEGFR-2.
We have recently described a comprehensive mechanism for
leptin upregulation of VEGF in breast cancer [27]. Leptin uses
several signaling pathways, including the activation of HIF-1a and
NF-kB, for the upregulation of VEGF in breast cancer cells under
normoxic conditions [27]. Moreover, leptin is a potent inducer of
IL-1 system in breast cancer cells [18]. Interestingly, leptin pro-
angiogenic signature in breast cancer was found linked to IL-1
signaling [18].
Notch, IL-1 and leptin are known pro-angiogenic inducers in
breast cancer [3]. In addition, leptin and Notch are mitogenic
factors for many cell types. Therefore, we hypothesized that their
actions could be intimately related. Results from the present
investigation strongly suggest that in addition of IL-1, leptin also
upregulates Notch receptors, ligands and target genes. Further-
Figure 3. Leptin-induced expression of Notch receptors and
targeted genes in mammary cancer cells are abrogated by CSL-
RNA knockdown. (A) Representative results of CSL-siRNA inhibition
on leptin upregulation of protein levels of Notch 1-3, activated NICD1
and Notch targeted genes, CSL, survivin and Hey2 in 4T1 cells as
determined by western blot (WB). The WB results were normalized to b-
actin as loading control and densitometric analysis of bands was
carried-out with the imageJ software for (B) CSL; (C) Notch1; (D) NICD1;
(E) Notch 2; (F) Notch 3; (G) Hey2 and (H) survivin. Cells cotransfected
with siRNA oligonucleotides (CSL-siRNA or control-siRNA) were treated
with leptin (0 and 1.2 nM) for 24 h. (a) P,0.05 when comparing protein
levels to cells treated with control-siRNA (basal) or CSL-siRNA. Data
(mean 6 standard error) representative results derived from a minimum
of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g003
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tion and migration was abrogated by the inhibition of Notch.
Moreover, leptin upregulation of VEGF/VEGFR-2 expression
was highly dependent of a novel unveiled crosstalk between Notch,
IL-1 and leptin (NILCO) in breast cancer cells.
Several genetic and pharmacologic approaches were used to
determine how leptin regulates Notch (ligands/receptors/targets)
and the impact of Notch signaling on leptin-induced VEGF/
VEGFR-2 expression in breast cancer cells. Remarkably, leptin
upregulates Notch at transcriptional/translational levels. Leptin
signaling upregulates the activity of CSL-promoter and Notch
mRNA expression as well as Notch activation. Leptin-induced
canonical/non-canonical signaling pathways were involved in
CSL promoter up-regulation. CSL (CBF or RBP-Jk) promoter
activity was linked to leptin-activated JAK2/STAT3, MAPK, PI-
3K/mTOR, p38 and JNK signaling pathways. Interestingly,
leptin upregulation of Notch was abrogated by blockade of IL-1R
tI. IL-1/IL-1R tI signals were previously found to mediate leptin
upregulation of VEGF/VEGFR-2 in breast cancer [18].
We have proposed that IL-1 could activate Notch signaling
pathway through NF-kB activity [3]. In line with this hypothesis,
Rel (a NF-kB subunit) was earlier identified as an activator of
Notch1 signaling pathway by inducing expression of JAG1
[30,31]. In addition, we have previously shown that leptin
upregulates both IL-1 [18] and VEGF by NF-kB dependent
mechanisms [27]. Present data suggest leptin upregulation of
VEGF/VEGFR-2 was also mediated by leptin-induced Notch
expression. These findings further suggest that leptin-induction
of Notch and IL-1 plays an important role in leptin pro-
angiogenic effects in breast cancer. Moreover, present findings
show for the first time that leptin and Notch collaborate for the
induction of cell proliferation/migration and that a complex
signaling network between Notch, IL-1 and leptin (NILCO) is
required for the upregulation of VEGF/VEGFR-2 in breast
cancer (Figure 8).
Leptin has previously been identified as a pro-proliferation and
anti-apoptotic factor that upregulates the expression of key
molecules for cell cycle, Cdk2 and cyclin D1 [25,26,32], activity
of Rb [33] and, apoptosis, Bcl-2 [34] and Bcl-xL [35]. Present
results showing leptin-mediated upregulation of Notch targets:
survivin (a recently identified pro-survival factor) [36,37] and
Hey2 (a repressor and mediator of Notch) [38], and induction of
cell proliferation and migration, further support the proliferative,
pro-survival and anti-apoptotic effects of leptin.
Figure 4. Leptin upregulates the CSL gene in mammary cancer cells. Leptin transcriptional activation of CBF (or CSL) promoter is linked to
several leptin-induced signaling pathways. (A) 4T1 cells were transiently transfected with a CBF-Luc reporter construct and incubated with leptin (0
and 1.2 nM) alone or plus siRNA oligonucleotides (SignalSilence control-siRNA and STAT3, MEK1, AKT1, mTOR, JNK, p38-siRNA). (B) Protein levels of
kinases after siRNA treatment were determined by WB analysis using b-actin as loading control. (C) 4T1 cells transfected with CBF-Luc reporter were
incubated with leptin alone or plus pharmacological inhibitors of JAK2/STAT3 (AG490, 30 mM), MEK/MAPK/ERK1/2 (PD98059, 30 mM), PI-3K/AKT1
(Wortmannin, 50 nM), PKC-Ca dependant (Go ¨6976, 30 mM), p38 kinase (SB203580, 2 mM), JNK (SP600125, 30 mM) and mTOR (Rapamycin, 20 nM)
signaling pathways for 24 h. Luciferase activity was determined as described (see M &M) and expressed as a percent of basal or leptin-treated cells. (a)
P,0.05 when comparing levels of luciferase activity to control (basal) or leptin-treated cells. Data (mean 6 standard error) representative results
derived from a minimum of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g004
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was found together with increased levels of IL-1a,E R a and OB-
R. Interestingly, all these leptin-mediated effects were abrogated
by inhibition of Notch activation or blockade of CSL expression.
Leptin has previously shown to transactivate ERa [39] and to
induce OB-R in breast cancer [18]. Moreover, Notch and ERa
crosstalk in breast cancer [40]. However, to the best of our
knowledge no previous reports on Notch-mediated upregulation
of ERa are available. E2 promoted 8-fold and 6-fold increase in
Notch1 and JAG1 expression, respectively, in breast cancer
MCF-7 cells [40]. On the other hand, in ERa expressing cells,
E2 inhibited Notch activity and affected NICD nuclear levels as
well as Notch-1 cellular distribution [41]. Therefore, leptin-
mediated induction of ERa through Notch signaling might
represent a negative feed-back loop for Notch expression in
breast cancer.
In conclusions, Notch-IL-1-Leptin crosstalk outcome (NILCO)
is essential for leptin-induced proliferation/migration as well as the
upregulation of VEGF/VEGFR-2 expression in breast cancer
cells. Leptin-induced proliferation and migration effects as well as
increased levels of pro-angiogenic factors in breast cancer cells
were related to an intact Notch signaling axis. Overall, NILCO
represents a novel crosstalk where signals from pro-angiogenic,
pro-inflammatory and developmental factors converge to promote
cell growth and tumor angiogenesis. NILCO could be a master
regulator of pro-angiogenic factors in breast cancer and likely
contribute to increase tumor angiogenesis and metastasic poten-
tial. Therefore, targeting this complex crosstalk could open the
development of new combinatory therapeutic possibilities, in
particular for the development of breast cancer linked to obesity
and hyperleptinemia (i.e., postmenopausal women). Combinatory
treatments of PEG-LPrAs [42] with drugs designed to prevent
Figure 5. Leptin-induced 4T1 cell migration and proliferation was abrogated by Notch inhibition. A) Representative results from
immunocytochemistry (ICC, hematoxylin staining) of leptin and DAPT effects on migration of 4T1 cells as compared to basal conditions. B)
Quantitative assessment of cell migration under the effects of leptin and DAPT. C) Representative results from ICC after addition of control-siRNA (Ctr-
siRNA), CLS-siRNA and leptin. D) Quantitative assessment of cell migration under the effects of leptin, CSL-siRNA and Crt-siRNA. E) Effects of leptin and
DAPT on 4T1 cell proliferation. F) Effects of leptin, Ctr-siRNA and CSL-siRNA on 4T1 cell proliferation. Results from cell migration (Boyden chamber cell
migration assay) and proliferation (MTT cell proliferation assay) were obtained after 24 h and normalized to basal conditions (see Material and
Methods). Data (mean 6 standard error) representative results derived from a minimum of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g005
NILCO Induces Growth/Migration and VEGF/VEGFR-2
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21467Notch and IL-1 oncogenic signal crosstalk may be advantageous
over drugs targeting individual players of NILCO.
Materials and Methods
Reagents and antibodies
Recombinant mouse leptin and mouse IL-1a/IL-1F1 and
VEGF Quantikine ELISA Kits were purchased from R & D
Systems (Minneapolis, MN). DAPT, N-[N-(3,5-difluorophenace-
tyl)-L-alanyl]-S-phenylglycine t-butyl ester, Monoclonal anti-
Notch1, b-actin antibodies were purchased from Sigma-Aldrich.
Fetal bovine serum (FBS) was obtained from Gemini Bioproducts
(West Sacramento, CA), RPIM-1640 medium and penicillin-
streptomycin cocktails were purchased from American Type
Culture Collection (ATCC) (Manassas, VA). Polyclonal anti-
Notch4, anti-OB-R-NH2 antibodies, monoclonal anti-IL-1R tI,
Figure 6. Leptin-Notch crosstalk regulates leptin-induced levels of pro-angiogenic and pro-inflammatory factors in mammary
cancer cells. (A) DAPT inhibition of c-secretase abrogated leptin transcriptional induction of VEGF (A); VEGFR-2 (B) and IL-1a mRNA (C) as
determined by real-time RT-PCR and normalized to the GAPDH expression. CSL-siRNA also inhibited leptin-induced effects on protein levels of VEGF
(D); VEGFR-2 (E) and IL-1a (F) mRNA. Representative results of DAPT (G) and CSL-siRNA (M) inhibition of leptin upregulation of protein levels of VEGF,
VEGFR-2, IL-1a,E R a and OB-R in 4T1 cells as determined by western blot (WB). The WB results were normalized to b-actin as loading control and
densitometric analysis of bands was carried-out with the imageJ software for VEGF (H and N); VEGFR-2 (I and O); IL-1a (J and P); ERa (K and Q) and OB-
R (L and R) in cells treated with leptin (0 and 1.2 nM) and DAPT for 24 h or cotransfected with CSL-siRNA and control (Ctr)-SiRNA, respectively. (a)
P,0.05 when comparing levels of antigens to basal conditions and control-siRNA. Data (mean 6 standard error) representative results derived from a
minimum of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g006
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control siRNA-A were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). STAT3, MEK1, AKT1, mTOR, SAPK/
JNK and p38 MAPK-siRNA and, SignalSilence control siRNA
were purchased from Cell Signaling (Danvers, MA). Polyclonal
anti-Notch2, 3, anti-IL-1a antibodies were obtained from Abcam
Inc (Cambridge, MA). Polyclonal anti-Hey2 was purchased from
Millipore (Temecula, CA). Polyclonal anti-survivin and STAT3,
MEK1, AKT1, p38 MAPK, SAPK/JNK antibodies were from
Cell Signaling (Danvers, MA). Polyclonal anti-mTOR antibody
was from Abcam (Cambridge, MA). Polyclonal anti-mouse
antibodies, anti-rabbit horseradish peroxidase (HRP) conjugates,
Figure 7. Inhibition of IL-1R tI signaling negatively impacts on leptin-mediated upregulation of Notch receptors and target genes in
mammary cancer cells. Anti-IL-1R tI antibodies abrogated leptin transcriptional induction of Notch1 (A); Notch2 (B); Notch3 (C) and targeted
genes, Hey2 (D) and survivin (E) in 4T1 cells as determined by real-time RT-PCR and normalized to the GAPDH expression. Blockade of IL-1R tI with
antibodies also inhibited leptin-induced effects on protein levels of Notch and targeted genes. Representative results of IL-1R tI blockade on leptin
upregulation of protein levels of Notch1, NICD1, Notch2, Notch3, Hey2) and survivin (F) as determined by western blot (WB). The WB results were
normalized to b\-actin as loading control and densitometric analysis of bands was carried-out with the imageJ software for Notch1 (G); NICD1 (H);
Notch2 (I); Notch3 (J), Hey2 (K) and survivin (M). 4T1 cells treated were treated with leptin (0 and 1.2 nM) and IL-1R tI antibodies or nonspecific
species-matched IgG (Control Ab) for 24 h. (a) P,0.05 when comparing Basal to Leptin+Control Ab and, (b) comparing Leptin+IL-1R tI Ab to
Leptin+Control Ab. Data (mean 6 standard error) representative results derived from a minimum of 3 independent experiments.
doi:10.1371/journal.pone.0021467.g007
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determination kits were purchased from Bio-Rad Lab. (Hercules,
CA). ECL Western blot stripping buffer was purchased from
Thermo Scientific (Rockford, IL). Dual-luciferase assay system and
pGL-3 plasmid were obtained from Promega (Madison, WI).
Mouse IL-1a and VEGF ELISA Kits were purchased from R & D
Systems (Minneapolis, MN). RNeasy Mini kits, DNase kits and
Superfect transfect reagents were obtained from Qiagen (Valencia,
CA). AG490, PD98059, Wortmannin, Go ¨6976, SB203580,
SP600125, Rapamycin, Endofree plasmid maxiprep kit, protease
inhibitor and phosphatase inhibitor cocktails 1 and 2 and other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
The mouse mammary tumor (MT) cell line 4T1 (CRL-2539;
ATCC), EMT6 (CRL-2755) and MMT060562 (MMT; CCL-51)
were cultured with complete RPMI-1640 containing 10% fetal
bovine serum (FBS), 100 units/ml penicillin and 100 mg/ml
streptomycin on uncoated flat-bottomed plastic plates (cell
densities of 1.0, 2.0 or 4.0610
5 cells/well for 24, 12 or 6 well
plates). Semi-confluent cells were starved for 24 h in basal medium
(RPMI-1640 without FBS) and treated with different compounds.
In all experiments triplicate wells, tubes and reactions were run
and repeated at least three times with different cell preparations.
Leptin dose-response effects
MT cells were starved as described above and incubated for
24 h with medium containing leptin (0, 0.6, 1.2, and 6.25 nM,
equivalent to 0, 10, 20 and 100 ng/ml). Proteins and mRNAs
were determined by western blot and real-time RT-PCR,
respectively. Protein concentrations in cell lysates were determined
by the Bradford method (Bio-Rad Lab).
Immunocytochemistry (ICC)
To assess leptin effects on the expression of Notch molecules
and their targets 4T1 cells (5610
5 cells/chamber) were cultured in
ICC-treated glass slides (BD FalconTM, Belford, MA) until 80%
confluence and incubated with 1.2 nM leptin for additional 24 h.
The slides were fixed in 10% formalin (3.7% formaldehyde in
PBS) for 24 h and incubated with antibodies for Notch1,4, DLL-
4, Hey2 and survivin for 4 h. Negative controls were made by
omitting primary antibodies. Mouse and rabbit ABC staining
systems (Santa Cruz, CA) were used according to the manufac-
turer’s instructions. Slides were counterstained with Mayer’s
hematoxylin and mounted with cover slips using an aqueous
mounting media. Images were obtained in a Leica TCS Confocal
microscopy at x200 magnifications.
Specific kinases involved in leptin-mediated effects
4T1 cells were starved as described above and incubated with
1.2 nM leptin and kinase inhibitors (AG490 for JAK2/STAT3,
30 mM; PD98059 for MEK/MAPK/ERK1/2, 30 mM; Wort-
mannin for PI-3K/AKT1, 50 nM; Go ¨6976 for PKC-Ca depen-
dant, 30 mM; SB203580 for p38 kinase, 2 mM; SP600125 for
JNK, 30 mM; and Rapamycin 20 nM for mTOR) for 24 h.
Reporter gene transfection and luciferase assay
Semi-confluent 4T1 cells were transiently cotransfected using
superFect transfection reagent (Qiagen) with 50 ng of a Renilla
reporter-luciferase control-plasmid and 500 ng of pGL3-CBF
plasmid containing firefly luciferase reporter gene (kindly provided
by Dr.Yizeng Yang, University of Pennsylvania). After 3 h
cotransfection, the cells were incubated with 1.2 nM leptin for
24 h. Luciferase activity in cell lysates was determined using the
dual-report assay system (Promega) according to the manufactur-
er’s instructions. Normalization was based on cotransfected Renilla
luciferase activities.
RNA extraction and real-time PCR
RNA was extracted from 4T1 cells using RNeasy Mini Kit
(Qiagen). First-strand cDNA was synthesized from total RNA
using SuperScript First-Strand Synthesis System with SuperScript
II reverse transcriptase according to the manufacturer’s protocols
(Invitrogen, Carlsbad, CA). The cDNA was used as a template in
real-time PCR reactions with QuantiTect SYBR-Green PCR
master-mix (Bio-RAD) and was run on an ABI PRISM 7700
machine. Real-time quantitative PCR reactions consisted of 1x
SybrGreen Supermix (Bio-Rad), 0.25mmol/L forward and reverse
primers, and 10 ng cDNA. Cycling conditions consisted of a three-
step amplification and melt curve analysis using the iQ5 Real-time
PCR Detection System (Bio-Rad). For generating a standard
curve, amplified cDNA from the reference sample detailed above
was used in a 5-fold dilution series of 100 to 0.16 ng cDNA per
reaction. Relative gene expression was calculated by dividing the
specific expression value (starting quantity, ng) by the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) expression value.
Primers used in the experiment were: Mouse Notch1 forward:
59-tgttgtgctcctgaagaa cg-39 and reverse: 59-tccatgtgatccgtgatgtc-39;
Mouse Notch2 forward: 59-gaggcgactcttctgctgtt-39 and reverse: 59-
ggtccatgtggtcagtgatg-39; Mouse Notch3 forward: 59-caatgcagtg-
gatgagcttg-39 and reverse: 59-ccaagaacagcggcgtct-39; Mouse
Notch4 forward: 59-ccgctgctgtgaacaacg-39 and reverse: 59-cacctc-
Figure 8. Notch, IL-1 and leptin crosstalk outcome (NILCO)
upregulates VEGF/VEGFR-2 and mediates leptin-induced
breast cancer cell proliferation/migration. Leptin up-regulates
Notch and IL-1 in breast cancer cells [18]. Leptin can directly [27], or
through IL-1 [18] and Notch, induce VEGF/VEGFR-2 up-regulation. VEGF
signaling could also upregulate Notch [45]. Leptin-induced proliferation
and migration of breast cancer cells was related to an intact Notch
signaling axis. NILCO could be a master process for the regulation of
breast cancer angiogenesis.
doi:10.1371/journal.pone.0021467.g008
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39 and reverse: 59-cagagctcagcagaggaacc-39; Mouse CSL forward:
59-caatgcttgaacttacaggaca-39 and reverse: 59-ggacccatctccaaccttc-
39; Mouse survivin forward: 59-gcggaggctggcttca-39 and reverse:
59-agaaaaaacactgggccaaatc-39; Mouse Hey2 forward: 59-
cctgtctcccaggctacact-39 and reverse: 59-ggcagtggtagctattctcctg-39;
Mouse DLL-4 forward: 59-agctgggtgtctgagtaggc-39 and reverse:
59-agaaggtgccacttcggtta-39; Mouse IL-1a forward: 59-tcgggagga-
gacgactctaa-39 and reverse: 59-aggtcggtctcactacctgtg-39; Mouse
VEGFR-2 forward: 59-gtgattgccatgttcttctggc-39 and reverse: 59-
ttcatctggatccatgacaa-39; Mouse VEGF forward:59-tacctccaccatgc-
caagtggt-39 and reverse:59-aggacggcttgaagatgtac-39. The GAPDH
was used as internal control using the following primers: forward:
59-tgcaccaccaatgcttag-39 and reverse: 59-ggatgcagggatgatgttc-39.
Western blot (WB)
Following cytokine and antibody treatment, cells were washed
once with ice-cold PBS and disrupted by homogenization in RIPA
buffer (Sigma) contained 0.1 mg/ml protease inhibitor, 1:100
phosphatase inhibitor cocktail 1 and 2. Cellular lysates were
centrifuged for 10 min at 24,000 g/4uC. Twenty-mg proteins were
loaded per lane and electrophoresis/electroblotting using specific
antibodies. Protein-bands were detected using SuperSignal West
Pico Chemiluminescent Substrate (Pierce) and exposed on Kodak
X-OMAT film (Kodak). Quantitative WB data were calculated
from densitometric analysis of bands with the NIH imageJ
software. The values were normalized to b-actin as loading
control.
Determination of IL-1 and VEGF levels by ELISA
Semi-confluent untransfected 4T1 (treated with DAPT; 5 uM/
0.1% DMSO final concentration) or transfected with siRNA
oligonucleotides were incubated with 1.2 nM leptin for 24 h (as
described above). Culture supernatants were used to assess leptin,
DAPT and CSL-siRNA effects on the levels of IL-1a and VEGF
proteins as determined by ELISA.
CSL-RNA knockdown
2.0610
5 4T1 cells were cultured in 6-well plates were starved as
described above and cotransfected with siRNA oligonucleotides
(CSL-siRNA and control) using Superfect reagent (Qiagen). After
4 h of transfection, the medium was changed to complete medium
containing 1.2 nM leptin for 24 h. Then, levels of Notch receptors
and targeted proteins were determined by WB analysis as
described above.
Leptin-induced kinase RNA knockdown and CSL-
luciferase assay
0.5610
5 4T1 cells were cultured in 24-well plates and starved as
described above. Then, cells were cotransfected with 50 ng of a
Renilla reporter-luciferase control-plasmid and 500 ng of pGL3-
CBF (CSL) plasmid as well as siRNA oligonucleotides (SignalSi-
lence control-siRNA and STAT3, MEK1, AKT1, mTOR, JNK,
p38-siRNA) using Superfect reagent (Qiagen). After 4 h of
transfection, the medium was changed to complete medium
containing 1.2 nM leptin for 24 h. Then, luciferase activity was
determined as described above. Protein levels of kinases after
siRNA treatment were determined by WB analysis using b-actin as
loading control.
MTT cell proliferation assay
MT cells were seeded 1610
4 per well in a 96-well plate. Cells
were starved as described above and incubated for 24 h in
medium containing 0 and 1.2 nM leptin plus 0.1% dimethylsulf-
oxide (DMSO), DAPT, control-siRNA and CSL-siRNA. Then,
20 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) (5 mg/ml) was added to each well. After 4 hours of
incubation at 37uC, cells were lysed by addition of 200 ml DMSO.
Absorbance was measured at 570 nm using a microplate reader
(Molecular Devices, CA).
Boyden chamber cell migration assay
Migration assay was performed as previously described [43,44].
4T1 cells (5610
4) suspended in starvation medium were added to
the upper chamber of an insert (6.4-mm diameter, 8-mm pore size;
BD Biosciences). - Inhibition of c-secretase: cells in the upper chamber
were suspended in basal medium plus 0.1% DMSO (Basal) or
DAPT (5 uM DAPT/0.1% DMSO) and the insert was placed in a
24-well plate containing starvation medium with or without
1.2 nM leptin. -CSL knockdown: Cells were previously transfected
for 4 h with Ctr-siRNA or CSL-siRNA and then placed in the
upper chamber. Then, the insert was placed in a 24-well plate
containing 0 or 1.2 nM leptin. Migration assays were carried out
for 24 h. Then, the cells in the lower side of the insert were fixed
with 3.7% formaldehyde. Cells were stained with hematoxylin and
cells on the upper side of the insert were removed with a cotton
swab. Six randomly selected fields (X10 objective) were photo-
graphed, and the migrated cells were counted.
Blockade of IL-1R tI
4T1 cells were starved as described and incubated with basal
medium containing 1.2 nM leptin and 0.1 mg/ml anti mouse IL-
1R tI antibody for 24 h which we described previously [18].
Nonspecific species-matched IgG2b served as negative controls.
Several proteins in cell lysates were analyzed by WB.
Data analysis
Student’s t-test was used for data analysis. Data (mean 6 standard
error) representative results derived from a minimum of 3
independent experiments. Values for p,0.05 were considered
statistically significant. The model included the main effects of
treatments and replicates.
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